Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
about
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisNeoadjuvant endocrine therapy in breast cancer: current role and future perspectivesChemotherapy in Premenopausal Breast Cancer PatientsBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsBisphosphonates in breast cancerThe promise of γδ T cells and the γδ T cell receptor for cancer immunotherapyBisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trialsZoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysisAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineImmune regulation of bone metastasisBone-Targeted TherapyBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaRandomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivoPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivoStatus of adjuvant endocrine therapy for breast cancer.Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Aromatase inhibitors-induced bone loss in early breast cancer.The microenvironment matters: estrogen deficiency fuels cancer bone metastasesCorrelation of mammographic density and serum calcium levels in patients with primary breast cancerAnti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancerReverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancerManagement options of breast cancer related osteoporosis.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.Factors associated with pregnancy attempts among female young adult cancer survivorsEffects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomyEffect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.Zoledronic acid in breast cancer: latest findings and interpretations
P2860
Q21132670-057A17FB-9E14-482C-909F-6951C9DFC64EQ26773012-6A5A2E53-2E77-49AE-8705-FA2A974B78B8Q26774622-1F3C3E3A-52AA-4BD1-8AEC-3D9FF6B07FF0Q26783705-FBD23BB8-16D2-4AA3-8BD8-166AD2E61FDBQ26824762-B2E2C1D5-3C28-4682-BFD7-809C67480384Q26859326-7ED963B5-7653-4189-A52C-48529F11344DQ26859775-FEC684BB-1479-4DD7-BD7A-5AB9AF820074Q26861586-A2A99EA2-1836-4193-A9C8-900CB488AD45Q26861745-8A3A5103-7685-4E27-84A6-88850AEEC526Q27002430-268D1AE3-4125-45B3-B6F2-FC7201F6D0BFQ27005871-18E61C6C-0F5A-4B3D-9A8B-9E4591BCA7DFQ28081294-11D37A5F-588A-4358-8963-348794F26BA0Q28081996-7AAE7172-26AC-44C0-98CF-CF29CCC095A9Q28551320-1CF6B216-03D8-486F-B23D-1A73AF0B9904Q30275126-C9862618-1A4A-490F-B967-61D184B7D8CBQ30543788-ADF40E55-C3F5-4BC6-B8AA-5D8ECE5D5BBAQ31150676-18BE07B6-83EE-4CCF-9B2C-90B87FA054D8Q33560459-1707B9F7-25BD-4CFF-BD04-9045A67E0B30Q33587199-5D04EC47-18AA-4FF7-8CED-FAD19CF4568DQ33692900-35A2B21F-5765-4B1D-A587-B4DD47163401Q33739138-B3E18C55-1811-4006-8D78-D9FB1667CE30Q33739204-4A548149-42BD-4D59-BED7-B0F677946552Q33752867-6E0AD4E0-BED1-4012-B7E4-C0D1CE5BE4DEQ33772299-DE94FDB6-306D-40F5-A194-D0E87189545AQ33775316-1206DFF9-25D2-49D7-8680-F8FD1DB8A6FFQ33920919-B191F5D9-BD79-4933-AC31-9EE537BB0ACAQ34042715-BF57D906-518B-4874-962F-7729A2D74321Q34113489-4CDA1930-41EE-4ED8-B19C-D6FE3546E77AQ34127953-2FDFAD0C-8B76-476B-9338-AF4848A5EA90Q34174466-BC8B26D4-AEEC-49FD-8B38-C49BB9B68BFCQ34230292-F1BA5938-6560-44C3-85BA-1B8B52E17F9DQ34245992-D813863C-B3F1-448D-BE55-597C5BD1B983Q34348233-862616FF-275F-4BAF-9DBD-39C8B477F2BCQ34459691-AEC3CFF6-A6F9-42EC-9F5A-36093049B776Q34581699-8100698A-D363-4E37-AF40-0C74C9B05904Q34583705-A49D4988-546E-429B-81CB-8F47A9957D10Q34611626-BCEFBF64-89CB-4490-8920-280D8EFE4257Q35073191-9894BEA0-6600-4080-8E2B-4CF6DC08ACBAQ35431110-7E3E776A-0D4F-45A2-A88D-142E43FA616CQ35534524-E7648ADF-8BE3-495D-9BA9-9662EE589832
P2860
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.
@en
Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.
@nl
type
label
Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.
@en
Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.
@nl
prefLabel
Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.
@en
Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.
@nl
P2093
P1433
P1476
Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial
@en
P2093
Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Brigitte Mlineritsch
Christian Fesl
Christian Menzel
Dietmar Heck
Ernst-Pius Forsthuber
Gerhard Hochreiner
Gero Luschin-Ebengreuth
Guenther Steger
Gunda Pristauz
P304
P356
10.1016/S1470-2045(11)70122-X
P577
2011-06-05T00:00:00Z